Avenue therapeutics announces closing of public offering of common stock

New york, dec. 15, 2021 (globe newswire) -- avenue therapeutics, inc. (or the “company”) (nasdaq: atxi), a company focused on the development of intravenous (“iv”) tramadol for the u.s. market, today announced the closing of its public offering of 1,910,100 shares of common stock at a public offering price of $1.07. the gross proceeds of the offering were approximately $2.0 million before deducting underwriting discounts, commissions and offering expenses. in addition, the company has granted aegis capital corp. a 45-day option to purchase up to an additional 286,430 shares of common stock to cover over-allotments, if any, at the public offering price, less the underwriting discount.
ATXI Ratings Summary
ATXI Quant Ranking